Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Pharmacol Drug Dev ; 6(4): 398-407, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27652589

RESUMO

We evaluated the pharmacokinetics and pharmacodynamics of prasugrel used in combination with aspirin in healthy Japanese subjects. All subjects received aspirin 100 mg/day. Subsequently, in the single-administration study, 23 subjects also received prasugrel 20 or 30 mg, and in the multiple-administration study, 20 subjects received a loading dose of prasugrel 20 or 30 mg on day 1, followed by a maintenance dose of prasugrel 5 or 7.5 mg/day, respectively, on days 2-5. In both studies, the plasma concentration of the active metabolite of prasugrel, R-138727, reached a maximum 0.5 hours after administration and rapidly decreased within 4 hours. In the single-administration study, the inhibitory effect on adenosine diphosphate-induced platelet aggregation was significantly higher in the prasugrel 20- and 30-mg groups than in the placebo group at all times (1-144 hours) after administration. In the multiple-administration study, a similar antiplatelet effect was found after both the loading dose and the maintenance dose and was maintained for 3-6 days after the last administration. There were study drug-related adverse events; however, all were mild, and none was clinically significant.


Assuntos
Aspirina/farmacocinética , Inibidores da Agregação Plaquetária/farmacocinética , Cloridrato de Prasugrel/farmacocinética , Adulto , Área Sob a Curva , Aspirina/administração & dosagem , Estudos Cross-Over , Método Duplo-Cego , Esquema de Medicação , Quimioterapia Combinada , Voluntários Saudáveis , Humanos , Japão , Piperazinas/sangue , Inibidores da Agregação Plaquetária/administração & dosagem , Testes de Função Plaquetária , Cloridrato de Prasugrel/administração & dosagem , Adulto Jovem
2.
Drug Metab Pharmacokinet ; 31(4): 285-91, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27474356

RESUMO

This randomized double-blind and placebo-controlled study assessed the pharmacodynamics and pharmacokinetics of prasugrel in healthy adult Japanese male subjects after single (n = 50) and multiple (n = 40) oral administration. With a single administration of prasugrel (2-30 mg), the plasma concentration of the active metabolite increased rapidly, reached a maximum at 30 min after administration, and then decreased rapidly within 4 h. The 5 mg and higher doses prevented ADP-induced platelet aggregation in a dose-dependent manner. Further analyses showed that 30 mg prasugrel exhibited the peak inhibition, and 20 mg prasugrel showed a nearly equivalent effect. With multiple doses (2.5-10 mg), the pharmacokinetic parameters on Day 1 and Day 7 were similar, and no accumulation attributable to multiple dosing was observed. The inhibitory effect on ADP-induced platelet aggregation increased with doses from 2.5 to 7.5 mg, and reached the peak level at 7.5 mg. Regarding safety, all of the drug-related adverse events observed were mild, and there were no clinically significant bleeding-related adverse events. This study indicates that a single oral administration of prasugrel at a dose of up to 30 mg and a maintenance dose of up to 10 mg are tolerated in Japanese healthy subjects.


Assuntos
Inibidores da Agregação Plaquetária/farmacocinética , Cloridrato de Prasugrel/farmacocinética , Adulto , Método Duplo-Cego , Voluntários Saudáveis , Humanos , Japão , Masculino , Inibidores da Agregação Plaquetária/efeitos adversos , Inibidores da Agregação Plaquetária/farmacologia , Cloridrato de Prasugrel/efeitos adversos , Cloridrato de Prasugrel/farmacologia , Adulto Jovem
3.
Eur J Pharm Sci ; 59: 94-103, 2014 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-24747579

RESUMO

Probe substrates for, and inhibitors of, specific transporters are desired to evaluate quantitatively the in vivo functions of transporters in humans. Based on published data, adefovir and benzylpenicillin were selected as organic anion transporter (OAT) 1- and OAT3-selective probe substrates, respectively. In human kidney slices, probenecid potently inhibited the uptake of both adefovir and benzylpenicillin with inhibition constant (Ki) values of 18.6±5.1 and 12.6±4.2µM, respectively, whereas p-aminohippurate (PAH) preferentially inhibited adefovir uptake. A clinical drug-interaction study involving healthy subjects was performed to investigate the dose-dependent inhibition potencies of probenecid and PAH on the renal clearance of the probe substrates. Adefovir or benzylpenicillin was coadministered with different oral doses of probenecid (500, 750, or 1500mg) or intravenous PAH infusion rates (70, 120, or 210mg/min/person) to the same subject using a crossover design. The renal clearance of adefovir was reduced by 45% and 46% in the subjects treated with the maximum dose of probenecid and PAH, respectively, which was in accordance with the results of in vitro inhibition study. On the other hand, renal clearance of benzylpenicillin was reduced by 78% in the subjects treated with the maximum dose of probenecid (1500mg), which could be explained by its in vitro Ki values. However, PAH unexpectedly increased the renal clearance of benzylpenicillin by 47%. These results suggest that adefovir and benzylpenicillin can be used as probe drugs for OAT1 and OAT3, respectively, and that PAH can be used to investigate the role of OAT1 in the urinary excretion of drugs in humans, whereas it may modulate other transport processes in the kidney.


Assuntos
Adenina/análogos & derivados , Rim/efeitos dos fármacos , Proteína 1 Transportadora de Ânions Orgânicos/antagonistas & inibidores , Transportadores de Ânions Orgânicos Sódio-Independentes/antagonistas & inibidores , Organofosfonatos/farmacocinética , Penicilina G/farmacocinética , Probenecid/farmacologia , Ácido p-Aminoipúrico/farmacologia , Adenina/sangue , Adenina/farmacocinética , Adulto , Interações Medicamentosas , Células HEK293 , Humanos , Técnicas In Vitro , Rim/metabolismo , Masculino , Proteína 1 Transportadora de Ânions Orgânicos/metabolismo , Transportadores de Ânions Orgânicos Sódio-Independentes/metabolismo , Organofosfonatos/sangue , Penicilina G/sangue , Adulto Jovem
4.
J Pharmacol Exp Ther ; 341(3): 626-33, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22389425

RESUMO

Indoxyl sulfate (IS) is an organic anion uremic toxin that accumulates in patients with chronic kidney disease (CKD). The aims of this study were to examine the kinetic profiles of IS in humans at a steady state after multiple doses of L-Trp, a precursor of IS, and the in vivo interaction of IS with the angiotensin-converting enzyme inhibitor quinapril, whose active metabolite is a substrate of organic anion transporter 3 (OAT3) in rats. First, 12-h kinetics after single doses of Trp (2, 4, and 8 g) were examined in two healthy volunteers. Second, 24-h kinetics after a single dose of 2 g of Trp was studied in six volunteers. Third, 35-h kinetics after single and multiple doses of 2 g of Trp were examined in five volunteers. In anesthetized rats, quinapril or probenecid, an inhibitor of OATs, was given intravenously before IS, and blood and urine samples were taken until 90 min. Trp and IS concentrations were determined by high-performance liquid chromatography. Ultrafiltration was used to measure serum unbound IS concentrations. Renal tubular secretion of IS accounted for more than 90% of its renal clearance in the steady state of serum IS levels after multiple doses in humans. In animals, the serum area under the curve of IS increased in conjunction with a decrease in renal clearances after coadministration of IS with quinapril or probenecid. It is concluded that quinapril may inhibit the urine excretion of IS via OAT3-mediated renal tubular transport in patients with CKD.


Assuntos
Inibidores da Enzima Conversora de Angiotensina/farmacocinética , Indicã/urina , Falência Renal Crônica/metabolismo , Rim/efeitos dos fármacos , Tetra-Hidroisoquinolinas/farmacocinética , Adulto , Animais , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Interações Medicamentosas , Humanos , Testes de Função Renal , Masculino , Transportadores de Ânions Orgânicos Sódio-Independentes/antagonistas & inibidores , Transportadores de Ânions Orgânicos Sódio-Independentes/metabolismo , Probenecid/farmacologia , Quinapril , Ratos , Toxinas Biológicas/metabolismo , Adulto Jovem
5.
Ann Nucl Med ; 25(6): 414-8, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21409348

RESUMO

OBJECTIVE: NMK36 is a novel PET tracer containing a synthetic amino acid analogue anti-[(18)F]FACBC as the active ingredient, and is under development for the use of tumor diagnosis. A Phase I clinical study of NMK36 was conducted to evaluate its safety, biodistribution, and radiation dosimetry in healthy volunteers. METHODS: Six healthy volunteers (Japanese male) received a bolus injection of NMK36 (174.4-201.4 MBq) intravenously. The safety of NMK36 was evaluated by monitoring signs/symptoms, electrocardiography, recording vital signs, and laboratory examinations at baseline and several time points in 6 days after injection. A total of 11 whole-body PET-CT scans were acquired up to 4 h post-injection, and venous blood and urine samples were also collected for 6 and 24 h post-injection, respectively. Based on the results of the biodistribution study, absorbed radiation dose was estimated by the MIRD method. RESULTS: Although two adverse events occurred after the injection of NMK36, they were mild and disappeared without any specific treatment. NMK36 preferentially accumulated in the pancreas and liver early after injection, followed by rapid clearance from the pancreas. Persistent uptake was observed in the skeletal muscle. NMK36 showed low uptake in the brain, and its urinary excretion was limited (5.40 ± 1.43% of the injected dose at 24 h post-injection). The liver was the critical organ, with a mean absorbed dose of 40.6 µGy/MBq. The estimated effective dose of NMK36 was 13.8 µSv/MBq, which was similar to or lower than those of radiotracers approved for clinical use including [(18)F]FDG. CONCLUSIONS: The findings of this study indicate that NMK36 is well tolerated. NMK36 has favorable characteristics for imaging brain and pelvic tumors, such as low brain uptake, slow urinary excretion, and high in vivo stability.


Assuntos
Aminoácidos/química , Ácidos Carboxílicos/química , Ciclobutanos/química , Tomografia por Emissão de Pósitrons/métodos , Aminoácidos/efeitos adversos , Aminoácidos/farmacocinética , Ciclobutanos/efeitos adversos , Ciclobutanos/farmacocinética , Humanos , Masculino , Traçadores Radioativos , Radiometria , Segurança , Adulto Jovem
6.
Blood ; 116(22): 4631-8, 2010 Nov 25.
Artigo em Inglês | MEDLINE | ID: mdl-20729467

RESUMO

Twenty percent to 30% of transient abnormal myelopoiesis (TAM) observed in newborns with Down syndrome (DS) develop myeloid leukemia of DS (ML-DS). Most cases of TAM carry somatic GATA1 mutations resulting in the exclusive expression of a truncated protein (GATA1s). However, there are no reports on the expression levels of GATA1s in TAM blasts, and the risk factors for the progression to ML-DS are unidentified. To test whether the spectrum of transcripts derived from the mutant GATA1 genes affects the expression levels, we classified the mutations according to the types of transcripts, and investigated the modalities of expression by in vitro transfection experiments using GATA1 expression constructs harboring mutations. We show here that the mutations affected the amount of mutant protein. Based on our estimates of GATA1s protein expression, the mutations were classified into GATA1s high and low groups. Phenotypic analyses of 66 TAM patients with GATA1 mutations revealed that GATA1s low mutations were significantly associated with a risk of progression to ML-DS (P < .001) and lower white blood cell counts (P = .004). Our study indicates that quantitative differences in mutant protein levels have significant effects on the phenotype of TAM and warrants further investigation in a prospective study.


Assuntos
Síndrome de Down/complicações , Fator de Transcrição GATA1/genética , Leucemia Mieloide/etiologia , Mutação , Transtornos Mieloproliferativos/complicações , Processamento Alternativo , Síndrome de Down/genética , Feminino , Expressão Gênica , Humanos , Recém-Nascido , Leucemia Mieloide/genética , Masculino , Transtornos Mieloproliferativos/genética , Fenótipo
7.
J Thorac Cardiovasc Surg ; 130(6): 1586-92, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16308003

RESUMO

OBJECTIVE: Reactive free radical species are thought to be involved in ischemic spinal cord injury. We investigated the effects of edaravone (Mitsubishi Pharma Co, Tokyo, Japan), a free radical scavenger, on spinal ischemia-reperfusion injury in a rabbit model. We also sought to estimate free radicals in the spinal cord using the microdialysis method. METHODS: Spinal cord ischemia was induced in New Zealand White rabbits. The animals were then divided into 4 groups. In the first experiment, which was carried out in group A (non-edaravone treated) and group B (edaravone treated), we assessed neurologic function and evaluated spinal cord histopathology. In the second experiment, which was performed in group C (non-edaravone treated) and group D (edaravone treated), we sequentially estimated the level of free radical species in the spinal cord with the microdialysis method. RESULTS: In the first experiment group B showed better neurologic function than group A. The number of viable neurons in the spinal cord gray matter was also higher in group B than in group A. The second experiment revealed that the level of free radical species was lower in group D at 75, 90, and 150 minutes after the beginning of reperfusion compared with levels seen in group C. The appearance of free radical species in the latter group was found to have a biphasic pattern, with peaks at 75 and 150 minutes after the beginning of reperfusion. CONCLUSION: Edaravone exerted a significant protective effect on the spinal cord against ischemia-reperfusion injury by suppressing the level of free radical species, which was demonstrated with the microdialysis method.


Assuntos
Antipirina/análogos & derivados , Sequestradores de Radicais Livres/uso terapêutico , Traumatismo por Reperfusão/prevenção & controle , Isquemia do Cordão Espinal/prevenção & controle , Animais , Antipirina/uso terapêutico , Edaravone , Masculino , Coelhos
8.
Brain Res ; 1060(1-2): 73-80, 2005 Oct 26.
Artigo em Inglês | MEDLINE | ID: mdl-16202986

RESUMO

It is reported that ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase (PARP). In this study, we examined the pharmacological profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion. In an in vitro study, KCL-440 exhibited potency with regard to inhibition of PARP activity, with an IC50 value of 68 nM. An in vivo pharmacokinetic study showed that the brain concentration of KCL-440 was sufficient to inhibit PARP activity during the intravenous infusion of KCL-440 at the rate of 1 mg/kg/h. KCL-440 at various doses or saline was administered for 24 h immediately after the MCA occlusion. Administration of KCL-440 led to a dose-dependent reduction in the infarct size at 24 h after MCA occlusion. Infarct sizes were 44.8% +/- 3.0% (n = 8), 40.5% +/- 1.1% (n = 8), 38.2% +/- 1.4% (n = 8), 35.1% +/- 2.1% (n = 8), 34.2% +/- 2.3% (n = 7), 32.6% +/- 1.9% (n = 8), and 31.0% +/- 2.1% (n = 5) at doses of 0, 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg/h. When compared to the control group, a statistically significant difference was observed in the doses that were higher than 0.03 mg/kg/h. When the infusion of KCL-440 (1 mg/kg/h, n = 8) was started at 1 h after the MCA occlusion, a significant reduction in infarct size was observed; this was not observed when KCL-440 infusion was started 2 or 3 h after the MCA occlusion. Furthermore, increased poly(ADP-ribose) immunostaining was confirmed at the ischemic border zone 2 h after the MCA occlusion, and it was reduced by KCL-440 treatment. These results suggest that KCL-440 is a possible neuroprotective agent with high blood-brain barrier permeability and high PARP inhibitory activity.


Assuntos
Encéfalo/efeitos dos fármacos , Inibidores Enzimáticos/administração & dosagem , Infarto da Artéria Cerebral Média/tratamento farmacológico , Fármacos Neuroprotetores/administração & dosagem , Inibidores de Poli(ADP-Ribose) Polimerases , Animais , Encéfalo/patologia , Células Cultivadas , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/análise , Inibidores Enzimáticos/farmacocinética , Masculino , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/análise , Fármacos Neuroprotetores/farmacocinética , Poli(ADP-Ribose) Polimerases/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
9.
Rinsho Byori ; 53(5): 395-9, 2005 May.
Artigo em Japonês | MEDLINE | ID: mdl-15966402

RESUMO

PURPOSE: S100B is a calcium-binding protein which exists in abundance in glial cells of the central nervous system (CNS). It is reported that the serum S100B level increase with various CNS diseases, such as stroke, head injury, schizophrenia, major depression and Alzheimer's disease. However, there are no reports on its reference values for the Japanese. The purpose of this study is to know the serum S100B concentrations of Japanese adults, free of any CNS diseases, according to sex, age and circadian rhythm. Moreover, the stability and reproducibility of its measurements of S100B in frozen serum over 7 months. METHODS: Volunteers were 26 male and 25 female of Japanese adults. Venous blood samples were collected at given times of a day and serum was obtained by centrifugation at 4 degrees C. An automated chemiluminescence analyzer "LIAISON" and exclusive reagent Sangtec 100 (DiaSorin, Italy), was used for measurement of serum S100B concentrations. RESULTS: The serum S100B concentrations in Japanese adults corresponded well, with the reported values in Asians. Differences by age and sex were not found. S100B did not how circadian variation. The serum S100B concentrations measured in two months and in nine months after venipuncture were almost the same. CONCLUSION: The measurement of S100B by "LIAISON" showed excellent reproducibility and reliability. Furthermore, stability of serum S100B stored at -80 degrees C was good.


Assuntos
Fatores de Crescimento Neural/sangue , Proteínas S100/sangue , Adulto , Idoso , Povo Asiático , Ritmo Circadiano , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Valores de Referência , Reprodutibilidade dos Testes , Subunidade beta da Proteína Ligante de Cálcio S100
10.
J Clin Apher ; 20(3): 171-84, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15892107

RESUMO

Inflammatory and/or autoimmune diseases like ulcerative colitis (UC) or Crohn's disease (CD) are debilitating chronic disorders that poorly respond to pharmacological interventions. Further, drug therapy has adverse effects that add to disease complications. The current thinking is that disorders like inflammatory bowel disease (IBD) reflect an over exuberant immune activation driven by cytokines including TNF-alpha. Major sources of cytokines include myeloid leukocytes (granulocytes, monocytes/macrophages), which in IBD are elevated with activation behavior and are found in vast numbers within the inflamed intestinal mucosa. Accordingly, myeloid cells should be the targets of therapy. Adacolumn is filled with cellulose acetate beads that selectively adsorb and deplete myeloid cells and a small fraction of lymphocytes (FcgammaR and complement receptors bearing cells). In one study, 20 steroid naive patients with moderate (n = 14) or severe (n = 6) UC according to Rachmilewitz despite 1.5-2.25 g/day of 5-aminosalicylic acid received 6 to 10 Adacolumn sessions at 2 sessions/week. Efficacy was assessed 1 week after the last session. The majority of patients responded to 6 sessions, 17 (85%) achieved remission. In 2 of the 3 non-responders, CAI was 8 and 12 in 1; all 3 had deep colonic ulcers at study initiation. Decreases were seen in total leukocytes (P = 0.003), % neutrophils (P = 0.003), % monocytes (P = 0.004), an increase in lymphocytes (P = 0.001), decreases in C-reactive protein (P = 0.0002), and rises in blood levels of soluble TNF-alpha receptors I (P = 0.0007), II (P = 0.0045). In a separate study, a case with very severe steroid refractory UC who received up to 11 sessions responded well and avoided colectomy. Further, myeloid cell purging with Adacolumn has been associated with the release of IL-1 receptor antagonist, suppression of TNF-alpha, IL-1beta, IL-6, IL-8, down-modulation of L-selectin and the chemokine receptor CXCR3. In conclusion, selective depletion of myeloid cells appears to induce anti-inflammatory effects and represents a non-pharmacological treatment for patients with active IBD. The treatment has a clear drug-sparing role. Changes in blood levels of inflammatory and anti-inflammatory factors are thought to contribute to the efficacy of this procedure.


Assuntos
Doenças Autoimunes/terapia , Colite Ulcerativa/terapia , Doença de Crohn/terapia , Leucaférese , Linfócitos/imunologia , Fagócitos/imunologia , Doenças Autoimunes/imunologia , Doenças Autoimunes/patologia , Colite Ulcerativa/imunologia , Colite Ulcerativa/patologia , Terapias Complementares/métodos , Doença de Crohn/imunologia , Doença de Crohn/patologia , Citocinas/imunologia , Feminino , Humanos , Leucaférese/métodos , Linfócitos/patologia , Masculino , Fagócitos/ultraestrutura
11.
Rinsho Byori ; 53(4): 275-8, 2005 Apr.
Artigo em Japonês | MEDLINE | ID: mdl-15915761

RESUMO

PURPOSE: In the development of new antithrombotic agents, the bleeding time has been used to evaluate the anti-hemostatic effects and predict the bleeding tendency. The Simplate bleeding time method (SIMP) has so far been used worldwide. However, the production of Simplate has been ceased. In this study, we introduced a new method which applies a thin taper needle to bleeding time measurement (IVY). There is no fundamental data of IVY in Japanese and the characters of two methods have never been compared in Japanese subjects. The purpose of this study is to find the standard values of bleeding time using IVY in 120 Japanese healthy male subjects and compare the inter-operator and inter-subject variability of IVY and SIMP. METHODS: In 120 subjects, bleeding time was measured by 1 operator using two different implements for IVY. In 6 volunteers, bleeding time was measured by 3 different operators using IVY and SIMP. RESULTS: The standards of bleeding time using IVY were 1'13"-2'44" (mean1'58" +/- 2SD, n = 117) by Glucoject Plus 2 and 1'4"-2'47" (mean1'56" +/- 2SD, n = 116) by auto-Lancet II. Average values by IVY were consistent, 1.8, 1.8 and 1.9 minutes among 3 operators. The corresponding values by SIMP were inconsistent, 5.3, 6.8 and 9.2 minutes. Bleeding time values measured by IVY were stable and consistent among subjects compared with values obtained by SIMP. CONCLUSION: The standard of bleeding time using IVY and less inter-operator and -subject variability of IVY were shown in this study. IVY might replace SIMP for measuring bleeding time.


Assuntos
Tempo de Sangramento/métodos , Tempo de Sangramento/normas , Adulto , Humanos , Japão , Masculino , Padrões de Referência
12.
Life Sci ; 76(2): 151-62, 2004 Nov 26.
Artigo em Inglês | MEDLINE | ID: mdl-15519361

RESUMO

N-[3-(4-Oxo-3,4-dihydro-phthalazin-1-yl)phenyl]-4-(morpholin-4-yl) butanamide methanesulfonate monohydrate (ONO-1924H) is a novel inhibitor of poly ADP-ribose polymerase (PARP). In this study, we examined the effects of ONO-1924H on cytotoxicity induced by hydrogen peroxide in PC12 cells in vitro and cerebral damage and neurological deficits induced by middle cerebral artery (MCA) thrombus occlusion in vivo in rat. In the in vitro cytotoxicity assay, exposure to 0.5 mmol/L hydrogen peroxide induced cell death in differentiated PC12 cells. ONO-1924H, a PARP inhibitor (Ki=0.21 micromol/L), reduced cell death in a concentration-dependent manner that was correlated with inhibition of PARP activation. A 50% reduction in cell death (EC50) was achieved with 2.4 micromol/L ONO-1924H. In the MCA occlusion model, ONO-1924H was injected intravenously at doses of 3, 10 and 30 mg/kg/h for 3 h, and cerebral damage and neurological deficits were estimated 24 h after MCA occlusion. ONO-1924H treatment led to a significant decrease in cerebral damage in the 10 mg/kg/h-treated group (P < 0.05) and the 30 mg/kg/h-treated group (P < 0.01). Further, ONO-1924H at doses of 30 mg/kg/h significantly (P < 0.05) improved neurological deficits. These findings suggest that the novel PARP inhibitor, ONO-1924H, affords effective neuroprotection and is a useful therapeutic candidate for the treatment of ischemic stroke.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , Morfolinas/uso terapêutico , Fármacos Neuroprotetores/farmacologia , Ftalazinas/uso terapêutico , Inibidores de Poli(ADP-Ribose) Polimerases , Animais , Isquemia Encefálica/complicações , Sobrevivência Celular/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/uso terapêutico , Transtornos Neurológicos da Marcha/tratamento farmacológico , Transtornos Neurológicos da Marcha/etiologia , Peróxido de Hidrogênio/toxicidade , Infusões Intravenosas , Masculino , Morfolinas/farmacologia , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/uso terapêutico , Células PC12 , Ftalazinas/farmacologia , Ratos , Ratos Sprague-Dawley
14.
Blood ; 103(7): 2610-6, 2004 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-14630814

RESUMO

Cerebral hemorrhage associated with antithrombotic and thrombolytic therapy in acute stroke continues to present a major clinical problem. Rupture of the cerebral microvasculature involves the degradation and remodeling of extracellular matrix. Here we demonstrated that the delayed administration of heparin 3 hours after photothrombotic middle cerebral artery occlusion (MCAO) caused cerebral hemorrhage in wild-type (WT) mice but not in tissue plasminogen activator (tPA)-deficient knockout (KO) mice. Heparin administration increased tPA activity and its mRNA expression at 6 and 12 hours after MCAO in the ischemic hemispheres of WT mice. The expression of tPA was enhanced in microglial cells in the ischemic border zone. We also observed an exacerbation of matrix metalloproteinase (MMP) 9 expression at the mRNA level and its conversion to an active form after heparin administration in the ischemic hemisphere in WT mice but not in tPA KO mice. The increased MMP 9 expression was localized in microglial cells and endothelial cells. These findings suggest that endogenous tPA, through the enhancement of MMP 9 expression and proteolytic activation, plays an essential role in the pathogenesis of heparin-produced cerebral hemorrhage. Targeting tPA, MMP 9, or both may provide a new approach for preventing cerebral hemorrhage associated with antithrombotic therapy for stroke in humans.


Assuntos
Arteriopatias Oclusivas/induzido quimicamente , Isquemia Encefálica/induzido quimicamente , Hemorragia Cerebral/patologia , Circulação Cerebrovascular/fisiologia , Heparina/farmacologia , Metaloproteinase 9 da Matriz/biossíntese , Artéria Cerebral Média , Ativador de Plasminogênio Tecidual/fisiologia , Animais , Arteriopatias Oclusivas/complicações , Sequência de Bases , Isquemia Encefálica/complicações , Hemorragia Cerebral/etiologia , Primers do DNA , Modelos Animais de Doenças , Indução Enzimática , Hibridização In Situ , Camundongos , Camundongos Knockout , Microcirculação/fisiologia , Reação em Cadeia da Polimerase , Ativador de Plasminogênio Tecidual/deficiência , Ativador de Plasminogênio Tecidual/genética
15.
Blood ; 102(8): 2960-8, 2003 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-12816863

RESUMO

Transient myeloproliferative disorder (TMD) is a leukemoid reaction occurring occasionally in Down syndrome newborn infants. Acute megakaryocytic leukemia (AMKL) develops in approximately 20% to 30% of the cases with TMD. Recently, acquired mutations in the N-terminal activation domain of the GATA-1 gene, encoding the erythroid/megakaryocytic transcription factor GATA-1, have been reported in Down syndrome-related AMKL (DS-AMKL). To understand the multistep leukemogenesis in Down syndrome, GATA-1 mutations were investigated in patients with TMD. We show here that mutations in the GATA-1 gene were detected in 21 of 22 cases with TMD. Most of the mutations in TMD were located in the regions including exon 2 and were essentially identical to those observed in DS-AMKL. In the DS-AMKL cell line, MGS, which itself expresses only a truncated mutant of GATA-1, expression of full-length GATA-1 induced the differentiation toward the erythroid lineage. However, expression of the short form of GATA-1 did not induce erythroid differentiation. These results indicate that expression of GATA-1 with a defective N-terminal activation domain contributes to the expansion of TMD blast cells and that other genetic changes contribute to the development of AMKL in Down syndrome.


Assuntos
Proteínas de Ligação a DNA/genética , Síndrome de Down/genética , Mutação , Transtornos Mieloproliferativos/genética , Fatores de Transcrição/genética , Fatores Etários , Diferenciação Celular , Linhagem Celular , Linhagem da Célula , DNA Complementar/metabolismo , Síndrome de Down/complicações , Fatores de Ligação de DNA Eritroide Específicos , Éxons , Feminino , Citometria de Fluxo , Fator de Transcrição GATA1 , Vetores Genéticos , Humanos , Immunoblotting , Recém-Nascido , Células K562 , Leucemia Megacarioblástica Aguda/genética , Masculino , Modelos Genéticos , Estrutura Terciária de Proteína , Retroviridae/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Análise de Sequência de DNA
16.
J Cardiovasc Pharmacol ; 41(4): 649-56, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12658068

RESUMO

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to upregulate endothelial nitric oxide synthase in isolated endothelial cells in a manner that is independent of their lipid-lowering effects. Nitric oxide inhibits polymorphonuclear leukocyte (PMN) adherence and attenuates cardiac dysfunction caused by PMNs after ischemia/reperfusion. Therefore, the authors hypothesized that a new statin, rosuvastatin, could attenuate PMN-induced cardiac dysfunction, and examined the effects of rosuvastatin in isolated ischemic (20 min) and reperfused (45 min) rat hearts perfused with PMNs. Rosuvastatin (0.25 or 1.25 mg/kg) given 18 h before ischemia/reperfusion significantly improved left ventricular developed pressure (P < 0.01) and the maximal rate of development of left ventricular developed pressure (+dP/dt(max), P < 0.01) compared with ischemia/reperfused hearts obtained from rats given 0.9% NaCl. The time point for the improved cardiac performance caused by rosuvastatin (1.25 mg/kg) was 20 min after reperfusion. In addition, rosuvastatin significantly reduced PMN adherence to the vascular endothelium and subsequent infiltration into the postischemic myocardium (P < 0.01). The nitric oxide synthase inhibitor N omega-nitro-l-arginine methyl ester (50 micromol/l) blocked these cardioprotective effects. These results provide evidence that rosuvastatin significantly attenuates PMN-induced cardiac contractile dysfunction in the isolated perfused rat heart.


Assuntos
Colesterol/sangue , Fluorbenzenos/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Pirimidinas , Sulfonamidas , Animais , Fluorbenzenos/farmacologia , Coração/efeitos dos fármacos , Coração/fisiologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Técnicas In Vitro , Traumatismo por Reperfusão Miocárdica/sangue , Ratos , Ratos Sprague-Dawley , Rosuvastatina Cálcica
17.
Life Sci ; 72(20): 2263-71, 2003 Apr 04.
Artigo em Inglês | MEDLINE | ID: mdl-12628446

RESUMO

Total flavones of Hippophae Rhamnoides L (TFH) are extracted from Sea buckthorn, a Chinese herbal medicine. Sea buckthorn has antioxidant, anti-ulcerogenic and hepato-protective actions, and its berry oil is reported to suppress platelet aggregation. Though it is frequently used for patients with thrombosis, the likely mechanism(s) and effects of TFH on thrombogenesis remain unclear. Thus, we have investigated the effect in-vivo of TFH on thrombogenesis and in vitro on platelet aggregation, comparing them to those of aspirin. We measured thrombotic occlusion time in a mouse femoral artery thrombosis model by the photochemical reaction between intravenously injected rose bengal and green light irradiation. In vitro platelet aggregation in whole blood was measured by single platelet counting. Thrombotic occlusion time was 8.5 +/- 0.6 min in the control group. TFH at a dose of 300 micro g/kg, intravenously administered 15 min before the rose bengal injection, significantly prolonged it to 11.6 +/- 1.0 min (P < 0.05), a similar effect on in-vivo thrombogenesis to that of aspirin. TFH at a concentration of 3.0 micro g/ml significantly (P < 0.01) inhibited in vitro platelet aggregation induced by collagen (2 micro g/ml) in a concentration dependent manner, in contrast TFH did not affect aggregation induced by arachidonic acid (80 micro M) and ADP (0.3 micro M). The results of the present study, in which TFH prevented in-vivo thrombogenesis, probably due to inhibition of platelet aggregation, suggest a possible clinical approach for the prevention of thrombosis.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Fibrinolíticos/farmacologia , Flavonoides/farmacologia , Hippophae , Agregação Plaquetária/efeitos dos fármacos , Trombose/prevenção & controle , Animais , Ácido Araquidônico/farmacologia , Aspirina/farmacologia , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Artéria Femoral/efeitos dos fármacos , Artéria Femoral/patologia , Técnicas In Vitro , Masculino , Camundongos , Camundongos Endogâmicos ICR , Trombose/patologia
18.
Eur J Pharmacol ; 455(1): 53-7, 2002 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-12433594

RESUMO

Diet can be the most important factor that influences risks for cardiovascular diseases. Genistein included in soy is one candidate that may benefit the cardiovascular system. Here, we investigated the inhibitory effects of genistein on thrombotic vessel occlusion in the mouse femoral artery using a photochemical reaction, and in vitro platelet aggregation in whole blood measured by single platelet counting. Genistein (10 mg/kg), intravenously administered 10 min before the rose bengal injection, significantly prolonged the thrombotic occlusion time from 6.1+/-0.4 to 8.4+/-0.8 min (P<0.05). Genistein at doses higher than 30 microM significantly (P<0.01) inhibited in vitro platelet aggregation induced by collagen (1 and 3 microg/ml). When 10 mg/kg genistein was intravenously administered, ex vivo platelet aggregation induced by collagen (1 and 3 microg/ml) was significantly suppressed (P<0.01). In conclusion, genistein prevented in vivo thrombogenesis and suppressed in vitro platelet aggregation. These results suggest that dietary supplementation of soy may prevent the progression of thrombosis and atherosclerosis.


Assuntos
Genisteína/farmacologia , Músculo Liso Vascular/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Trombose/prevenção & controle , Análise de Variância , Animais , Artéria Femoral , Injeções Intravenosas , Masculino , Camundongos , Camundongos Endogâmicos ICR
19.
Br J Clin Pharmacol ; 54(5): 453-62, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12445023

RESUMO

AIMS: The pharmacokinetics and safety profile of JTE-522, 4-(4-cyclohexyl-2 methyloxazol-5-yl)-2-fluorobenzensulphonamide, a novel selective cyclooxygenase-2 inhibitor were investigated in healthy male volunteers. METHODS: Initially, as a pilot study, five groups of two subjects were given oral doses of 3-100 mg of JTE-522. After safety assessment, subjects were given 150 and 200 mg of JTE-522. The effect of food-intake on the pharmacokinetics of JTE-522 at a dose of 150 mg was examined. In the multiple-dose study, subjects were given 150 mg of JTE-522 once a day for 7 days. Concentrations of unchanged JTE-522 in plasma, blood and urine were determined by high performance liquid chromatography (h.p.l.c.). Concentrations of metabolites were estimated with h.p.l.c. chromatograms and calibration curves for quantification of unchanged JTE-522. RESULTS: In the course of this study, no serious abnormality attributable to the test drug was observed, suggesting that JTE-522 was well tolerated in healthy subjects. In a single-dose study, the concentrations of JTE-522 in blood were much higher than the corresponding concentrations in plasma. JTE-522 was readily distributed to blood cells and percentage distribution into blood cells was more than 99.0%. However, the values of Cmax in blood at doses of 100, 150, 200 mg JTE-522 were 15241, 20445 +/- 3918 (16333-24556), 20965 +/- 3260 (17544-24386) ng ml-1, respectively. These findings suggest that JTE-522 has a high affinity for blood cells and the distribution into blood cells is limited at the higher doses of over 100 mg. In a multiple dose study, pharmacokinetic parameters including t1/2 and AUC after the fourth administration were comparable with that of the seventh administration. Thus, these findings suggest the absence of accumulation on the multiple-dosing of JTE-522. CONCLUSIONS: These results indicate that JTE-522 has an acceptable pharmacokinetic profile for clinical use without any serious adverse events as we verified in healthy young male volunteers.


Assuntos
Benzenossulfonatos/farmacocinética , Inibidores de Ciclo-Oxigenase/farmacocinética , Isoenzimas/antagonistas & inibidores , Oxazóis/farmacocinética , Administração Oral , Adulto , Área Sob a Curva , Benzenossulfonatos/administração & dosagem , Benzenossulfonatos/efeitos adversos , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/administração & dosagem , Inibidores de Ciclo-Oxigenase/efeitos adversos , Relação Dose-Resposta a Droga , Meia-Vida , Humanos , Masculino , Proteínas de Membrana , Oxazóis/administração & dosagem , Oxazóis/efeitos adversos , Projetos Piloto , Prostaglandina-Endoperóxido Sintases
20.
Brain Res ; 945(2): 242-8, 2002 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-12126886

RESUMO

The Na(+)/H(+) exchanger (NHE) is activated during ischemia-reperfusion in an effort to restore intracellular pH to normal levels. The NHE is recognized to exist as a distinct protein in the plasma membranes of a variety of cells. We investigated the pharmacological effects of a Na(+)/H(+) exchanger inhibitor, SM-20220 (N-(aminoiminomethyl)-1-methyl-1-H-indole-2-carboxamide methanesulfonate), on ischemic brain damage, edema and neutrophil accumulation at 72 h after middle cerebral artery (MCA) occlusion in a rat MCA occlusion model. SM-20220 was intravenously administered as a bolus injection immediately after occlusion, followed by a continuous infusion over 2.5 h. At 72 h after occlusion, the infract area was measured using hematoxylin-eosin staining and, using the same slices, neutrophils in the brain were immuno-stained with anti-myeloperoxidase (n=11). In a separate study, rat behavior was scored and scaled, and brains removed for the determination of water content by the dry-weight method. SM-20220 significantly (P<0.05) attenuated cerebral infarct volume, water content, and the neutrophil accumulation at 72 h after the MCA occlusion, and ameliorated neurological deficits. SM-20220, an NHE inhibitor prevented the progress of cerebral ischemic damage and edema following MCA occlusion in rats though a possible mechanism that may be due to the inhibition of neutrophil accumulation. The NHE in neutrophils may enhance the progress of cerebral damage following cerebral ischemia-reperfusion.


Assuntos
Amidas/farmacologia , Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/patologia , Inibidores Enzimáticos/farmacologia , Indóis/farmacologia , Artéria Cerebral Média/fisiologia , Neutrófilos/patologia , Trocadores de Sódio-Hidrogênio/antagonistas & inibidores , Animais , Autorradiografia , Comportamento Animal/efeitos dos fármacos , Comportamento Animal/fisiologia , Água Corporal/metabolismo , Encéfalo/patologia , Química Encefálica/efeitos dos fármacos , Química Encefálica/fisiologia , Edema Encefálico/tratamento farmacológico , Edema Encefálico/patologia , Isquemia Encefálica/psicologia , Circulação Cerebrovascular , Masculino , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...